danshenol A
Names
Biological Activity
[Description]:
Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC50 of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research[1][2][3][4].
[Related Catalog]:
[Target]
IC50: 0.1 μM (Aldose reductase)[3]
[In Vitro]
Danshenol A (10 nM; pretreatment for 1 h) 单独处理显示对 ICAM-1 在 mRNA 和蛋白质水平的表达没有影响。Danshenol A 显着逆转 TNF-α 诱导的 ICAM-1 表达和随后的单核细胞粘附,以及升高的活性氧 (ROS) 生成和 NOX4 表达[1]. Danshenol A 通过 NOX4 依赖性 IKKβ/NF-κB 通路抑制 TNF-α 诱导的 ICAM-1 表达和随后的单核细胞与内皮细胞的粘附[1]。 Danshenol A (1, 3, and 10 μM; pretreated for 35 min) 恢复血管紧张素 II 诱导的心肌细胞凋亡。此外,Danshenol A 抑制心肌细胞线粒体氧化还原信号通路[2]。 Danshenol A 抑制 K562 (IC50 = 0.53 μg/mL)、T-24 (IC50 = 7.94 μg/mL)、QGY (IC50 = 4.65 μg/mL) 和 Me180 (IC50 = 6.89 μg/mL) 细胞系的活性[4]。 Western Blot Analysis[1] Cell Line: HUVEC cells Concentration: 10 nM Incubation Time: Pretreatment for 1 h Result: Showed no effect on the ICAM-1 expression at both mRNA and protein levels.
[In Vivo]
Danshenol A (0.3-3mg/kg;口服;每天一次;持续 12 周) 改善 SHR 大鼠的血压、心脏损伤和心肌胶原体积,并改善心功能。Danshenol A 修复线粒体结构/功能,减轻心肌氧化应激[2]。 Animal Model: Forty male spontaneously hypertensive rats (SHR) and eight male Wistar-Kyoto (WKY) rats at the age of 16 weeks[2] Dosage: 0.3 mg/kg, 1 mg/kg, 3 mg/kg Administration: Orally administration; daily; for 12 weeks Result: Ameliorated blood pressure, cardiac injury, and myocardial collagen volume and improved cardiac function.
[References]
Chemical & Physical Properties
[ Density]:
1.31±0.1 g/cm3
[ Boiling Point ]:
571.5ºC at 760 mmHg
[ Molecular Formula ]:
C21H20O4
[ Molecular Weight ]:
336.38100
[ Flash Point ]:
206.6ºC
[ Exact Mass ]:
336.13600
[ PSA ]:
63.60000
[ LogP ]:
3.27500
[ Vapour Pressure ]:
6.74E-14mmHg at 25°C
[ Index of Refraction ]:
1.653